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Abstract
Background Many patients with gastric cancer present with late stage disease. Palliative gastrectomy remains a contentious interven-
tion aiming to debulk tumour and prevent or treat complications such as gastric outlet obstruction, perforation and bleeding.
Methods We conducted a systematic review of the literature for all papers describing palliative resections for gastric cancer and
reporting peri-operative or survival outcomes. Data from peri-operative and survival outcomes were meta-analysed using random
effects modelling. Survival data from patients undergoing palliative resections, non-resective surgery and palliative chemother-
apy were also combined. This study was registered with the PROSPERO database (CRD42019159136).
Results One hundred and twenty-eight papers which included 58,675 patients contributed data. At 1 year, there was a signifi-
cantly improved survival in patients who underwent palliative gastrectomy when compared to non-resectional surgery and no
treatment. At 2 years following treatment, palliative gastrectomy was associated with significantly improved survival compared
to chemotherapy only; however, there was no significant improvement in survival compared to patients who underwent non-
resectional surgery after 1 year. Palliative resections were associated with higher rates of overall complications versus non-
resectional surgery (OR 2.14; 95% CI, 1.34, 3.46; p < 0.001). However, palliative resections were associated with similar peri-
operative mortality rates to non-resectional surgery.
Conclusion Palliative gastrectomy is associated with a small improvement in survival at 1 year when compared to non-resectional
surgery and chemotherapy. However, at 2 and 3 years following treatment, survival benefits are less clear. Any survival benefits
come at the expense of increased major and overall complications.
Keywords Stomach neoplasms . Gastrectomy . Survival
Introduction
Primary gastric cancer (GC) is the fifth most common malig-
nancy worldwide and frequently presents at a late and incur-
able stage [1]. The majority of patients present with either
stage 3 or 4 disease and many will have already developed
metastasis [2, 3] with many patients surviving less than a year
after initial diagnosis [4, 5]. Although the incidence of GC is
declining, there are still over 5000 new diagnoses every year
in the UK alone and it continues to be the 3rd biggest cause of
cancer-related deaths globally [6–8].
Localised GC is often managed with combined resection
and chemotherapy owing to a significant body of evidence
which demonstrates its survival benefit compared to surgery
alone [9–11]. However, advanced GC is generally regarded as
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incurable and resection is often not considered owing to the
extent of local tumour invasion and/or the presence of distant
metastases [12]. Progressive tumour growth means patients
are at risk of tumour-related complications such as gastric
outlet obstruction, perforation and bleeding, all of which can
lead to reduced quality of life, emergency surgery and ulti-
mately a reduction in life span.
Palliative gastrectomy (PG), comprising of either total,
subtotal or distal gastrectomy, is recognised as a treatment
for alleviating or preventing these complications, yet its use
remains a contentious topic owing to the high-risk nature of
the procedure and mixed evidence for its survival benefit in
advanced GC [13–15].
Previous evidence has not only demonstrated the absence
of any survival benefit from PG but has also shown no im-
provement in quality of life and an increased number of
chemotherapy-associated adverse events [14, 15]. The
REGATTA trial, the only phase III randomised control trial
comparing chemotherapy alone and gastrectomy followed by
chemotherapy showed no survival benefit and concluded that
palliative gastrectomy in patients with metastatic gastric can-
cer cannot be justified [14]. Some authors have criticised the
REGATTA trial for including large numbers of patients re-
quiring total gastrectomy, using oral rather than intra-venous
chemotherapy treatment regimens and grouping patients with
different sites of metastatic disease together as these factors
could affect the interpretation of the results [16].
There is a growing body of non-randomised evidence sug-
gesting that PG not only provides symptomatic relief but can
also extend survival [17–20]. With continued uncertainty sur-
rounding the efficacy of PG in advanced GC, the aim of this
systematic review and meta-analysis was to analyse both op-
erative and survival outcomes following palliative gastrecto-
my for advanced primary gastric cancer.
Methods
Search Strategy
This study was prospectively registered with the PROSPERO
database of systematic reviews (CRD42019159136). A systematic
literature search was undertaken by one researcher (SK) using the
PubMed, EMBASE and Cochrane Library databases on 25th
January 2020. Search terms included ‘palliative gastrectomy’ or
‘palliative total gastrectomy’ or ‘palliative subtotal gastrectomy’ or
‘palliative resection’ and ‘stomach neoplasms’ or ‘gastric cancer’
or ‘gastric adenocarcinoma’ or ‘stomach cancer’. Outcomes in-
cluding ‘post-operative complications’, ‘mortality’, ‘disease free
survival’, ‘overall survival’ and ‘quality of life’ were included in
the search. Full details of the literature search terms used can be
found in Supplementary table 1. The results of the literature search
were reported in accordancewith the PRISMAguidelines (Fig. 1).
Inclusion and Exclusion Criteria
Inclusion criteria were (1) studies reporting outcomes
following palliative gastrectomy for primary gastric adenocar-
cinoma and (2) human studies published in the English
language. Exclusion criteria were (1) review articles, case re-
ports, letters, editorials and conference abstracts; (2) studies
which exclusively report outcomes for oesophagectomy,
oesophagogastrectomy, surgical bypass procedures or cura-
tive gastrectomy; (3) studies in which outcomes for palliative
gastrectomy were combined with the outcomes of other
surgical procedures; (4) gastric cancers other than pri-
mary adenocarcinoma.
Fig. 1 PRISMA diagram of study inclusion
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All studies generated by the literature search were screened
by three independent reviewers for their relevance based on
the title, abstract and study type using the above inclusion/
exclusion criteria. All duplications were excluded. In the in-
stance, there was uncertainty about the relevance of a study,
the advice was sought of all authors and a final decision was
made. Where studies were excluded, the reason for exclusion
was verified by a fourth reviewer. For those studies which
remained following this initial screening process, full texts
were obtained and reviewed in detail by the same three to
produce a final list of all included studies.
Study Outcomes
The primary outcome was overall survival following
palliative gastrectomy for primary gastric cancer.
Secondary outcomes included overall post-operative
complications, major complications, anastomotic leak,
pulmonary complications, mortality, overall survival
rates (1-, 2-, 3- and 5-year), recurrence-free survival
and self-reported quality of life measures.
Data Extraction
Data was extracted for all included studies by three
independent reviewers and any queries were resolved
by consensus with all authors. Data was extracted under
the following headings: year of publication, study dura-
tion, study country, study design, number of study cen-
tres, use of comparison groups, overall study sample
size, treatment group sample size, stage of gastric can-
cer, definition of palliative gastrectomy, tumour loca-
tion, metastasis location, tumour histology, risk factors
and chemotherapy use. In addition to extracting data for
patients undergoing palliative gastrectomy, where avail-
able, data was extracted for other treatment groups un-
der the broad headings of ‘curative gastrectomy’, ‘che-
motherapy only’, ‘non-resectional surgery’ and ‘no sur-
gery’. This data was collected to enable a comparison to
the main intervention of interest, palliative gastrectomy.
Assessment of Methodological Quality
Three researchers assessed the methodological quality of
all included studies using the Newcastle-Ottawa Quality
Assessment Scale (NOS) for all comparative cohort
studies. This score was omitted in the instance that a
study was a non-comparative cohort study, for which
the NOS is not valid. The overall grading of each study
is given in results supplementary table 1.
Statistical Analysis
This systematic review and meta-analysis was conducted in ac-
cordancewith the recommendations of the Cochrane Library and
MOOSE guidelines [15]. For categorical variables, analysis was
performed by calculating the odds ratio (OR). For survival anal-
ysis, relative risk (RR) statistics were calculated. Random effects
modelling, using the DerSimonian-Laird method was used for
the meta-analysis of outcomes. Heterogeneity between studies
was assessed using the I2 value in order to determine the degree
of variation not attributable to chance alone. I2 values were con-
sidered to represent low, moderate and high degrees of hetero-
geneity where values were < 25%, 25–75%, and > 75%, respec-
tively. Assessment of small study bias was carried out by visual
assessment of funnel plots and egger regressions. Statistical sig-
nificancewas consideredwhen p< 0.05. Statistical analyseswere
performed using R statistical software (R version 3.5.2, R
Foundation for Statistical Computing, Vienna, Austria).
Results
Study Characteristics
The literature search identified 128 studies reported according to
the PRISMAguidelines as shown in Fig. 1. Studies identifiedwere
from North America (n = 14), South America (n = 7), Australasia
(n = 72) and Europe (n = 35). The majority of studies were retro-
spective cohort studies (n = 123), with the remainder prospective
cohort studies (n = 3) and RCTs (n = 2). Sixty-one studies iden-
tified were reported after 2010, the remaining 67 studies before
2010. Of the studies that reported on either clinical or pathological
tumour stage, 41 of 91 studies consisted entirely of patients with T
stage 4 disease. On average across 91 studies reporting the per-
centage of patients with T stage 4 disease, 68.6% of patients had T
stage 4 disease. There was considerable variation in whether re-
sections were defined as palliative due to the advanced T stage of
the primary tumour or due to distant metastasis (Table 1). Across
studies containing a proportion of patients with metastatic disease,
9 studies of 93 included only patientswith lymph nodemetastases,
whilst 84 included patients with a mixture of metastases sites. Of
these, 41 of 84 studies included patients with liver metastases, 14
studies included patients with lung metastases and 40 included
patients with peritoneal metastases.
Reporting Standards and Methodological Quality
Study quality was assessed using NOS, median 8, ranging
between 5 and 9, indicating generally high quality cohort
studies (Supplementary Table 1). A summary of studies
reporting the impact of intervention type on morbidity and
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fifteen studies reported data on overall complications
comparing patients undergoing palliative surgery com-
pared to non-resectional procedures. Palliative gastrecto-
my was associated with an increase in overall compli-
cations compared to non-resectional surgery (OR 2.14;
95% CI, 1.34, 3.46; p < 0.001; I2 = 46%) (Table 3).
Egger regression analysis suggested a significant publi-
cation bias (p = 0.004), with a Duval and tweedie im-
puted OR and 95% CI, 1.43 (0.81, 2.54). Seventeen
studies reported data on overall complications compar-
ing palliative surgery to curative intent surgery.
Palliative surgery was associated with an increase in
overall complications compared to curative surgery
(OR 1.46; 95% CI, 1.18, 1.79; p < 0.001; I2 = 47%).
No significant publication bias was identified through
egger regression testing (p = 0.871).
Major Complications
Two studies reported data on major complications com-
paring patients undergoing palliative gastrectomy com-
pared to non-resectional procedures. Palliative surgery
was associated with an increase in major complications
compared to non-resectional surgery (OR 3.41; 95% CI,
1.42, 8.20; p < 0.001; I2 = 0%) (Table 3). Insufficient
data were available for egger regression testing. Nine
studies reported data on overall complications compar-
ing palliative surgery to curative intent surgery.
Palliative surgery was associated with an increase in
major complications compared to curative surgery (OR
1.51; 95% CI, 0.87, 2.52; p = 0.12; I2 = 84%). No
significant publication bias was identified through egger
regression testing (p = 0.702).
Anastomotic Leak
Eleven studies reported data on anastomotic leak com-
paring patients undergoing palliative surgery compared
to non-resectional procedures. Palliative Surgery was as-
sociated with an increase in anastomotic leak compared
to non-resectional surgery (OR 2.35; 95% CI, 1.14,
4.84; p = 0.02; I2 = 0%) (Table 3). Egger regression
analysis suggested an insignificant publication bias (p =
0.654). Thirteen studies reported data on anastomotic
leak comparing palliative surgery to curative intent sur-
gery. Palliative surgery was associated with similar rates
of anastomotic leak compared to curative surgery (OR
1.01; 95% CI, 0.56, 1.42; p = 0.98; I2 = 71%). No
significant publication bias was identified through egger
regression testing (p = 0.945).
Table 2 Differences in short
post-operative outcomes compar-
ing non-resectional procedures
and curative intent resections to
palliative surgery
N Odds ratio Confidence intervals p value
Palliative gastrectomy versus non-resectional procedures
Overall complications 15 2.15 1.34–3.46 < 0.001
Major complications 2 3.41 1.42–8.20 0.01
Anastomotic leak 11 2.35 1.14–4.84 0.02
Peri-operative mortality 19 1.10 0.73–1.66 0.66
Palliative gastrectomy versus curative intent resection
Overall complications 17 1.46 1.18–1.79 < 0.001
Major complications 9 1.51 0.87–2.62 0.12
Anastomotic leak 13 1.01 0.56–1.85 0.98
Peri-operative mortality 29 1.89 1.34–2.65 < 0.001
Palliative gastrectomy versus non-resectional procedures (published post-2010)
Overall complications 8 1.493 1.043–2.138 < 0.001
Major complications 2 3.41 1.42–8.20 0.01
Anastomotic leak 6 2.311 0.653–8.175 0.194
Peri-operative mortality 3 0.361 0.082–1.59 0.178
Palliative gastrectomy versus curative intent resection (published post-2010)
Overall complications 6 1.536 1.013–2.328 0.043
Major complications 2 1.294 0.392–4.272 0.672
Anastomotic leak 5 0.789 0.212–2.915 0.724
Peri-operative mortality 11 1.397 0.696–2.821 0.348
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Early Post-operative Mortality
Nineeen studies reported data on early post-operative mortal-
ity comparing patients undergoing palliative surgery com-
pared to non-resectional procedures. Palliative surgery was
not associated with a significant increase in early post-
operative mortality compared to non-resectional surgery (OR
1.10; 95% CI, 0.73, 1.66; p = 0.66; I2 = 21%). Egger regres-
sion analysis suggested an insignificant publication bias (p =
0.495). Twenty-nine studies reported data on early post-
operative mortality comparing palliative surgery to curative
intent surgery. Palliative surgery was associated with an in-
crease in early post-operative mortality compared to curative
surgery (OR 1.89; 95%CI, 1.34, 2.65; p = 0.98; I2 = 43%). No
significant publication bias was identified through egger re-
gression testing (p = 0.673).
Long-term Survival
1-Year Survival
Twenty studies reported numbers surviving at 1 year follow-
ing palliative surgery, non-resectional surgery, chemotherapy
or no treatment. Palliative surgery was associated with an
improved 1-year survival compared to non-resectional surgery
(RR 0.421, 0.197–0.909; p = 0.044), chemotherapy (RR
0.734, 0.575–0.963; p = 0.026) and no treatment (OR 0.381,
0.176–0.827; p = 0.015) (Table 4).
2-Year Survival
Seventeen studies reported numbers surviving at 2 years fol-
lowing palliative surgery, non-resectional surgery, chemother-
apy or no treatment. Palliative surgery was associated with an
improved 2-year survival compared to non-resectional surgery
(RR 0.432, 0.150–1.194; p = 0.44), chemotherapy (RR 0.508,
0.352–0.744; p = 0.04) and no treatment (RR 0.277, 0.239–
0.326; p < 0.001) (Table 4).
3-Year Survival
Eight studies reported numbers surviving at 3 years following
palliative surgery, non-resectional surgery, chemotherapy or
no treatment. Palliative surgery was associated with an im-
proved 3-year survival compared to chemotherapy (RR
Table 3 Relative risk and 95%
confidence intervals of different
treatment strategies versus
palliative gastrectomy at 1-, 2-, 3-
and 5-year survival
N RR 95% CI p I2
1-year survival
Palliative gastrectomy vs. chemotherapy only 5 0.734 0.559–0.963 0.0256 81%
Palliative gastrectomy vs. non-resectional procedures 7 0.421 0.197–0.909 0.0435 82%
Palliative gastrectomy vs. no intervention 8 0.381 0.176–0.827 0.0147 91%
2-year survival
Palliative gastrectomy vs. chemotherapy only 6 0.508 0.352–0.744 0.040 81%
Palliative gastrectomy vs. non-resectional procedures 5 0.432 0.150–1.194 0.4434 85%
Palliative gastrectomy vs. no intervention 6 0.277 0.239–0.326 < 0.001 0%
3-year survival
Palliative gastrectomy vs. chemotherapy only 4 0.578 0.298-1.07 0.2285 70%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 3 0.225 0.181-0.284 < 0.001 0%
Papers published post-2010 subgroup
1-year survival
Palliative gastrectomy vs. chemotherapy only 5 0.734 0.559-0.963 0.0256 81%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 1 - - - -
2-year survival
Palliative gastrectomy vs. chemotherapy only 6 0.508 0.347-0.742 < 0.001 81%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 2 1.101 0.407–2.974 0.562 0%
3-year survival
Palliative gastrectomy vs. chemotherapy only 5 0.567 0.299–1.074 0.0816 54%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 1 - - - -
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0.578, 0.298–1.12; p = 0.23) and no treatment (RR 0.225,
0.181–0.284; p < 0.001) (Table 4).
Discussion
This review identifies an association between palliative gas-
trectomy and improved overall survival for patients with gas-
tric cancer treated palliatively, compared to chemotherapy,
non-resectional surgery and no treatment, at 1 year. After 1
year, palliative gastrectomy was not associated with a survival
benefit over non-resectional surgery. Significantly, palliative
gastrectomy was associated with increased morbidity com-
pared to non-resectional surgery; however, this was not simul-
taneously associated with increased peri-operative mortality.
This study encompasses all relevant trials up until January
2020. Surgical techniques and oncological therapies have im-
proved markedly during the inclusion period which extends
from 1974 to 2018. Potential improvements in clinical prac-
tice may have enabled improved patient selection for gastrec-
tomy. Improvement in surgical and oncological techniques
concurrently with improved patient selection aims to optimise
survival for those fit for some form of resection. Current
patient selection uses criteria such as patient performance sta-
tus, co-morbidity, extent of disease and importantly patient
choice. The extent to which biology of the disease dictates
outcome is poorly understood, however, with ongoing re-
search into the genetics of gastric cancer [142, 143] with the
potential to further refine selection in the future, further
optimising outcomes [144, 145].
The study, although comprehensive, including 128 papers
which included 58,675 patients did include studies from over
40 years, some of which may have limited clinical relevance;
however, subgroup analyses of papers published in the last
decade did not show significantly different results. The study
did not incorporate outcomes for palliative gastrectomy which
were combined with the outcomes of other surgical proce-
dures such as cytoreductive surgery (CRS) which together
may improve survival for those who would otherwise receive
palliative oncological therapies. The precise reason for pallia-
tive surgery and the extent of disease burden was heteroge-
neous throughout the studies identified and the lack of current
clinical guidelines or consensus on this topic makes this ex-
tremely difficult to standardise. Very few studies reported on
health-related quality of life measures, following palliative
gastrectomy. In an era where health research aims to re-
Table 4 Relative risk and 95%
confidence intervals of different
treatment strategies versus
palliative gastrectomy at 1-, 2-, -
3- and 5-year survival
N RR 95% CI p I2
1-year survival
Palliative gastrectomy vs. chemotherapy only 5 0.734 0.559–0.963 0.0256 81%
Palliative gastrectomy vs. non-resectional procedures 7 0.421 0.197–0.909 0.0435 82%
Palliative gastrectomy vs. no intervention 8 0.381 0.176–0.827 0.0147 91%
2-year survival
Palliative gastrectomy vs. chemotherapy only 6 0.508 0.252–0.997 0.045 81%
Palliative gastrectomy vs. non-resectional procedures 5 0.442 0.071–2.697 0.4434 85%
Palliative gastrectomy vs. no intervention 6 0.277 0.239–0.326 < 0.001 0%
3-year survival
Palliative gastrectomy vs. chemotherapy only 4 0.578 0.298–1.12 0.2285 70%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 3 0.225 0.181-0.284 < 0.001 0%
Papers published post-2010 subgroup
1-year survival
Palliative gastrectomy vs. chemotherapy only 5 0.734 0.559–0.963 0.0256 81%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 1 - - - -
2-year survival
Palliative gastrectomy vs. chemotherapy only 6 0.508 0.347-0.742 < 0.001 81%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no intervention 2 1.101 0.407-2.974 0.562 0%
3-year survival
Palliative gastrectomy vs. chemotherapy only 5 0.567 0.299–1.074 0.0816 54%
Palliative gastrectomy vs. non-resectional procedures 1 - - - -
Palliative gastrectomy vs. no Intervention 1 - - - -
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focus on patient perceived benefits, any measured improve-
ment in health-related quality of life could be considered more
important than small improvements in quantity of life with co-
morbid surgical procedures.
Challenges remain as how to determine treatment choice
based on the extent of local disease and whether patients with
T4b disease should receive surgery. There is significant vari-
ation in unit practice as to whether patients receive a
multivisceral resection (MVR) or palliative surgery. MVR is
associated with a significant morbidity and mortality in excess
of the accepted risks of gastrectomy [146]. This is particularly
evident when distal pancreatectomy is required to achieve an
R0 resection [147]. Despite this, performing an MVR to
achieve an R0 resection does provide a survival advantage
and should be a potential treatment option in patients deemed
sufficiently fit for surgery of this magnitude [148].
The role of surgery in metastatic gastric cancer continues to
evolve as treatment options mirror treatment advances in other
malignancies. Hepatectomy for colorectal liver metastasis has
been show to improve survival compared to other palliative
treatment options [149]. There is now evidence to demonstrate
that hepatectomy for gastric cancer metastases is associated
with longer median overall survival than palliative treatments
for selected patients [150, 151]. Peritoneal carcinomatosis is
predominantly treated with systemic chemotherapy; however,
cytoreductive surgery and heated intraperitoneal chemothera-
py (CRS and HIPEC) have been shown in highly selected
patients to provide a survival advantage [152, 153].
Pressurised intraperitoneal aerosol chemotherapy has also
been demonstrated to be safe and provides beneficial anti-
tumour activity in patients with gastric cancer peritoneal car-
cinomatosis [154]. Although this systematic review and
meta-analysis does not specifically examine the potential
beneficial adjuncts to gastrectomy, it is important to
identify that achieving a survival advantage with sur-
gery may require a multi-modal approach.
It is currently not clear to what extent oncological therapies
could be used in concordance with surgery and whether pa-
tients undergoing palliative resection should be offered neo-
adjuvant and adjuvant chemotherapy, as standard, particularly
in an era where FLOT (5-fluorouracil, folinic acid, oxaliplatin,
docetaxel) is becoming the gold standard of oncological treat-
ment for patients with oesophago-gastric cancer. The
REGATTA trial randomised patients to gastrectomy with
D1 lymphadenectomy without any resection of metastatic le-
sions and adjuvant chemotherapy or chemotherapy alone and
found no significant difference in overall survival [14].
Subsequently, there has been a trend away from the use of
surgery in improving survival in patients who are known to
have metastatic gastric cancer [155].
The AIO-FLOT 3 trial compared patients with limited met-
astatic disease who benefited from neoadjuvant FLOT to pa-
tients with resectable disease and to patients with extensive
metastatic disease [12]. The trial identified that patients with
limited metastatic disease who received neoadjuvant chemo-
therapy and proceeded to surgery showed a favourable surviv-
al when compared to expected survival for patients with met-
astatic disease. The trial did not determine the additional ben-
efit of surgery in patients with limited metastatic disease who
showed a good response to chemotherapy. Improvements in
chemotherapy in conjunction with improving surgical tech-
niques inclusive of a D2 gastrectomy and metastatectomy
may provide improved survival for patients who previously
may have been palliated.
Oncological therapies continue to develop and immuno-
therapy is increasingly playing a role in gastric cancer as is
evident with HER2 positive tumours and the use of
trastuzumab [156]. Further studies continue into the impor-
tance of HER-2 blockade in the form of trastuzamab and
pertuzamab in conjunction with FLOT in the Petrarca Trial
which is yet to report [157]. Increasingly immunotherapy tri-
als continue to examine the benefits of PD1/PD-L1 and
CTLA4 blockade and will likely be incorporated into the treat-
ment pathways of advanced gastric cancer [158–160].
Conclusions
Palliative gastrectomy is associated with significant morbidity
over and above non-resectional palliative surgery and gastrecto-
my for curative intent. Palliative gastrectomy may offer an early
survival advantage compared to oncological therapies given in
isolation; however, this does not extend beyond a couple of years
and may well result from patient selection biases. Further re-
search into the biology of gastric cancer and improved techniques
for patient selection are required to improve overall survival for
patients with palliative gastric cancer.
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